Method of treating a blood disorder associated with C1q-mediated activation of the classical complement pathway by administering an anti-C1q antibody

A method of treating a blood disorder associated with C1q-mediated activation of the classical complement pathway in a subject in need thereof, comprising administering to the subject a Cle inhibitor an anti-C1q antibody, wherein the anti-C1q antibody is a full-length antibody or antigen-binding fragment thereof comprising a light chain variable domain comprising an HVR-L1 having the amino acid sequence of SEQ ID NO:

• 5, an HVR-L2 having the amino acid sequence of SEQ ID NO:
• 6, and an HVR-L3 having the amino acid sequence of SEQ ID NO:
• 7;
• and a heavy chain variable domain comprising an HVR-H1 having the amino acid sequence of SEQ ID NO:
• 9, an HVR-H2 having the amino acid sequence of SEQ ID NO:
• 10, and an HVR-H3 having the amino acid sequence of SEQ ID NO:
• 11;
• and wherein:
• (i) the full-length antibody is administered to the subject by intravenous injection or infusion once a week, once every other week, or once a month at a dose between 10 mg/kg and 150 mg/kg, or at a dose between 75 mg/kg and 100 mg/kg;
• (ii) the full-length antibody is administered to the subject by subcutaneous or intramuscular injection at a dose between 1 mg/kg and 10 mg/kg, or at a dose between 3 mg/kg and 5 mg/kg;
• or
• (iii) the antigen-binding fragment is administered to the subject by intravenous injection or infusion, by intramuscular injection, or by subcutaneous injection at a dose between 0.1 mg/kg and 50 mg/kg, or at a dose between 0.3 mg/kg and 10 mg/kg.